Mild Cognitive Impairment Nutrition Market Intelligence: Size, Share and Growth Outlook Through 2036
By Key Ingredient, Product Type, Product Form, End User — Global Forecast to 2036
By Brevintel Editor•August 2026•PDF + Excel
Market Size (2026)
$420M
Market Forecast (2036)
$1.2B
CAGR (2026-2036)
10.6%
Mild cognitive impairment nutrition is projected to rise from USD 420.1 million in 2026 to USD 1,150.4 million by 2036 at 10.6% CAGR. Earlier identification of cognitive decline is increasing opportunities for preventive nutrition discussions before more intensive care pathways are required. Danone Nutricia reported in March 2025 that it introduced pharmacy-based AI screening tools designed to support earlier recognition of mild cognitive impairment. Companies in the cognitive health supplement market need evidence-bounded products that fit daily routines before later care intensifies.
Key Market Trends & Insights
Mild cognitive impairment nutrition is projected to rise from USD 420.1 million in 2026 to USD 1,150.4 million by 2036 at 10.6% CAGR.
Danone Nutricia reported in March 2025 that it introduced pharmacy-based AI screening tools designed to support earlier recognition of mild cognitive impairment.
USD 420.1 million in 2026 and USD 1,150.4 million by 2036 at a 10.6% CAGR.
In June 2025, the United States Census Bureau reported 61.2 million people aged 65 and older in 2024.
DHA formulators use omega-3 concentrates to build cognitive supplements and multinutrient products across established oral formats. Aker BioMarine reported in May 2025 that its Lysoveta trial would enroll 138 adults aged 50 to 75 who reported mild memory complaints.
Based on key ingredient, omega-3 - DHA blends are projected to account for 34.9% in 2026 due to broad compatibility. Established consumer recognition lowers the education burden for brands using familiar fatty-acid terminology.
Commercial adoption of EPA DHA omega-3 ingredients depends on dose density and oxidation control across repeated home-use regimens. Poor sensory performance can reduce adherence even with an ingredient fitting the intended cognitive proposition.
What makes omega-3 - DHA blends central to the key ingredient category?.
Market Overview
Overview
USD 420.1 million in 2026 and USD 1,150.4 million by 2036 at a 10.6% CAGR.
Market Dynamics
Overview
Earlier recognition expands the addressable population while evidence limits conversion and better product fit provides the clearest revenue route.
Segmentation Analysis
Segment Overview
The mild cognitive impairment nutrition market is segmented by key ingredient, product type, product form, end user, sales channel and region.
Key ingredient includes omega-3 - DHA blends, B-vitamin complexes, Fortasyn-type multinutrients, botanical nootropics and others.
Product type covers medical foods, cognitive-support supplements, fortified foods and beverages and others.
Product form includes capsules / softgels, RTD, powders and others.
End user covers home - self-care, memory clinics and hospitals and others.
Sales channel includes online / DTC, retail pharmacy, supermarkets and hypermarkets, specialty and health stores and others.
What makes omega-3 - DHA blends central to the key ingredient category?
DHA formulators use omega-3 concentrates to build cognitive supplements and multinutrient products across established oral formats.
Aker BioMarine reported in May 2025 that its Lysoveta trial would enroll 138 adults aged 50 to 75 who reported mild memory complaints.
Based on key ingredient, omega-3 - DHA blends are projected to account for 34.9% in 2026 due to broad compatibility.
Established consumer recognition lowers the education burden for brands using familiar fatty-acid terminology.
Commercial adoption of EPA DHA omega-3 ingredients depends on dose density and oxidation control across repeated home-use regimens.
Regional Outlook
Regional Overview
The 2.5 percentage-point range separates South Korea's personalization-led outlook from Japan's functional-food route.
South Korea and USA form the upper group at 11.1% and 10.2% CAGR.
UK and Germany occupy the middle at 9.8% and 9.3%.
Japan records 8.6% as documentation requirements temper conversion.
South Korea gains from regulated personalized health-functional-food services with defined safety controls.
USA pairs broad consumer access with active enforcement against unsupported cognitive claims.
UK diagnosis pathways give nutrition brands clearer professional contact around earlier cognitive decline.
Germany offers pharmacy access while European claim rules narrow consumer cognitive messaging.
Japan's memory support supplement route uses formal functional-claim notifications but requires evidence documentation from companies.
Similar growth rates therefore conceal materially different claim controls and channel economics.
The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.
Country-wise Analysis
Competitive Landscape
Overview
Danone Nutricia (Souvenaid), Nestle Health Science, Aker BioMarine, Kirin Holdings, SFI Health (Equazen), Reckitt (Neuriva), Thorne, and Quincy Bioscience are the notable companies profiled in this market.
Key Companies Covered
Danone Nutricia (Souvenaid)
Nestle Health Science
Aker BioMarine
Kirin Holdings
SFI Health (Equazen)
Reckitt (Neuriva)
Thorne
Quincy Bioscience
Table of Contents
The complete report includes additional chapters, data tables, and company profiles beyond this preview.
Key Takeaways
Market Size and CAGR
Top Growth Driver
Fastest Growing Segment
Leading Region
Key Companies
Emerging Opportunities
Executive Summary
Global Market Outlook
Demand-side Trends
Supply-side Trends
Technology Roadmap Analysis
Analysis and Recommendations
Analyst Perspective (What is happening? Why now? What should investors know?)
